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Background: Mesenchymal transformation of pulmonary endothelial cells contributes to the formation of a
metastatic microenvironment, but it is not known whether this precedes or follows early metastasis formation. In
the present work, we characterize the development of nitric oxide (NO) deficiency and markers of endothelial–
mesenchymal transition (EndMT) in the lung in relation to the progression of 4T1 metastatic breast cancer injected
orthotopically in mice.
Methods: NO production, endothelial nitric oxide synthase (eNOS) phosphorylation status, markers of EndMT in the
lung, pulmonary endothelium permeability, and platelet activation/reactivity were analyzed in relation to the
progression of 4T1 breast cancer metastasis to the lung, as well as to lung tissue remodeling, 1–5 weeks after 4T1
cancer cell inoculation in Balb/c mice.
Results: Phosphorylation of eNOS and NO production in the lungs of 4T1 breast cancer-bearing mice was
compromised prior to the development of pulmonary metastasis, and was associated with overexpression of Snail
transcription factor in the pulmonary endothelium. These changes developed prior to the mesenchymal phenotypic
switch in the lungs evidenced by a decrease in vascular endothelial-cadherin (VE-CAD) and CD31 expression, and
the increase in pulmonary endothelial permeability, phenomena which coincided with early pulmonary metastasis.
Increased activation of platelets was also detected prior to the early phase of metastasis and persisted to the late
phase of metastasis, as evidenced by the higher percentage of unstimulated platelets binding fibrinogen without
changes in von Willebrand factor and fibrinogen binding in response to ADP stimulation.
Conclusions: Decreased eNOS activity and phosphorylation resulting in a low NO production state featuring
pulmonary endothelial dysfunction was an early event in breast cancer pulmonary metastasis, preceding the onset
of its phenotypic switch toward a mesenchymal phenotype (EndMT) evidenced by a decrease in VE-CAD and CD31
expression. The latter coincided with development of the first metastatic nodules in the lungs. These findings
suggest that early endothelial dysfunction featured by NO deficiency rather than EndMT, might represent a primary
regulatory target to prevent early pulmonary metastasis.
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Breast cancer kills approximately 40,000 people worldwide
each year and is a leading cause of cancer death in women
[1]. Breast cancer progression is associated with inflamma-
tory responses that promote neoplastic disease and reduce
survival of patients regardless of their age, race, tumor
stage, and body mass index [2]. Inflammation is both a
marker and the causative factor of endothelial dysfunction
and promotes cancer growth and metastasis. In particular,
adhesion of metastatic cancer cells to the activated vascular
endothelium and their subsequent transendothelial migra-
tion are regulated by a number of endothelium-dependent
mechanisms favoring or inhibiting premetastatic micro-
environment formation. Indeed, factors released from dys-
functional endothelium activate some inflammatory
signaling pathways in cancer cells, promoting their inva-
siveness [3, 4], while endothelial vasoprotective mediators
including nitric oxide (NO) inhibit adhesiveness of cancer
cells to endothelial cells [5].
Decreased NO production, frequently associated with a
decreased phosphorylation of eNOS [6], represents the
early hallmark of endothelial dysfunction [7]. NO prevents
endothelial inflammatory activation [8]. When its produc-
tion or bioavailability is compromised, expression of
cell-surface adhesion molecules on the endothelium surface
such as vascular cell adhesion molecule 1 (VCAM-1) is in-
creased [8]. Endothelial dysfunction can also be activated
by platelet-released substances that trigger endothelial in-
flammation. Furthermore, proinflammatory activation of
endothelial cells favors monocyte and neutrophil binding as
well as platelet rosetting on the leukocyte–endothelial cell
surface [9], facilitating anchoring of cancer cells to activated
endothelial surface concomitantly with leukocytes forming
platelet–tumor cell–leukocyte heteroaggregates [10]. For-
mation of such aggregates in low-resistance vascular beds,
such as in the pulmonary circulation, irrevocably disturbs
the laminar blood flow that could further potentiate patho-
logical endothelial activation [11].
Endothelial dysfunction can also be manifested by in-
creased endothelial permeability linked with disassem-
bly of intercellular adherens junction proteins (i.e.,
VE-cadherin (VE-CAD)) between endothelial cells [12].
An increase in endothelial permeability is the critical
event enabling cancer cells to extravasate and form me-
tastases [13–16]. Endothelial permeability is negatively
regulated by mechanisms maintaining endothelial
barrier integrity, such as the Slit2–ROBO4–ROBO1
signaling pathway [17–19]. Finally, dysfunctional endo-
thelial cells may lose their endothelium-like phenotype
via TGF-β-dependent or TGF-β-independent expres-
sion of transcription factors such as Snail [20–22],
which are reported to suppress endothelium-specific
genes [23–25] that initiate endothelial-to-mesenchymal
transition (EndMT) [26].Since there is no comprehensive study characterizing
progression of endothelial dysfunction in the metastatic
organ from the very early premetastatic phase until the late
metastatic phase of the disease, in the present study we
aimed to characterize alterations in the phenotype of pul-
monary endothelium in relation to the progression of 4T1
metastatic breast cancer injected orthotopically into mice.
For that purpose, we measured NO production, eNOS
phosphorylation status, markers of EndMT, endothelial
permeability, as well as lung tissue remodeling and platelet
activation from 1 to 5 weeks after 4T1 cancer cell inocula-
tion into Balb/C mice. We demonstrate that early impair-
ment of NO-dependent function in the lungs precedes the
decrease in expression of endothelium-specific proteins in-
dicating an EndMT phenotypic switch, the latter coinciding
with the development of early metastatic nodules in the
lungs.
Methods
Animals
Two hundred and forty female Balb/C mice, 7–11 weeks
old, were purchased from Charles River Lab (Germany)
and divided into healthy control mice (n = 30) injected
orthotopically with Hank’s Balanced Salt Solution (HBSS;
IIET, Poland) and mice (n = 210) injected orthotopically
with 1 × 104 4T1 murine breast cancer cells suspended in
HBSS. The mice injected with 4T1 cells were euthanized
(ketamine and xylazine, 100 and 10 mg/kg, respectively) in
the 1st, 2nd, 3rd, 4th, and 5th week after cancer cell injec-
tion. Healthy control mice were euthanized concomitantly
with mice in the 5th week of the disease. Throughout the
experiment, all animals were housed 5–6 mice per cage, in
a temperature-controlled environment (22–25 °C), main-
tained on a 12-h light/day cycle and given unlimited access
to food (AIN; Zoolab, Krakow, Poland) and water. Experi-
mental procedures involving animals were accepted by the
First Local Ethical Committee on Animal Testing at Jagiel-
lonian University (Krakow, Poland; permit no. 140/2013)
and the Second Local Ethical Committee on Animal Test-
ing in the Institute of Pharmacology, Polish Academy of
Sciences (Krakow, Poland; permit no. 41/2017).
Cell culture
The mouse mammary adenocarcinoma 4T1 cells were ob-
tained from the American Type Culture Collection (ATCC,
USA) and were cultured in RPMI 1640-Glutamax medium
(Sigma-Aldrich, Poland) supplemented with 10% fetal bo-
vine serum (Gibco, Thermo Fisher Scientific, Poland),
1.0 mM sodium pyruvate (Sigma-Aldrich, Poland), and anti-
biotic antimycotic solution (100 units/ml penicillin and
100 μg/ml streptomycin, 25 μg/ml amphotericin B) (Sig-
ma-Aldrich, Poland). Cells were cultured at 37 °C in a hu-
midified atmosphere containing 5% CO2. For inoculations,
only 4T1 cells at the second passage were used. Prior to the
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tase solution (Sigma-Aldrich, Poland), centrifuged
(300 × g, 4 °C, 5 min), counted, suspended in Hank’s
Balanced Salt Solution (HBSS; IIET, Poland) at the
appropriate concentration, and inoculated into the
mammary gland of female Balb/C mice. All cell cul-
tures were routinely tested for Mycoplasma contamin-
ation (MycoAlert Mycoplasma Detection Kit; Lonza).
Measurement of breast cancer primary tumor and
pulmonary metastasis
Body mass was monitored throughout the experiment. To
assess the primary tumor growth, the primary tumor vol-
ume was measured with calipers each week as described
by Kim et al. [27]. After mice euthanasia, primary tumors,
lungs, and spleens were excised, weighed, and saved for
further analysis. Lungs designated for assessment of me-
tastasis were fixed in formalin and cut into lobes, and the
pulmonary metastatic nodules were counted on their sur-
face. After assessment of pulmonary metastasis, lung lobes
were paraffin-embedded, cut into 5-μm slices, and stained
with hematoxylin and eosin (H&E) to visualize pulmonary
metastasis. The lung cross-sections were scanned with a
BX51 microscope equipped with the virtual microscopy
system dotSlide (objective magnification 20×; Olympus,
Japan). To visualize the reorganization of extracellular
matrix in the lungs during disease progression, the lung
cross-sections were stained with Unna Orcein staining for
elastin fibers. Subsequently, randomly chosen visual fields
for mice in each experimental group were photographed
in such a way that only the lung parenchyma was visible
without major pulmonary blood vessels and bronchi. The
pictures were subjected to segmentation in Ilastik (devel-
oped by the Ilastik team, with partial financial support by
the Heidelberg Collaboratory for Image Processing,
HHMI Janelia Farm Research Campus and CellNetworks
Excellence Cluster), and the relative number of pixels cor-
responding to elastin fibers in each experimental group
was calculated using ImageJ [28].
Measurement of NO production in the lungs
Colloidal Fe2+(DETC)2 was used for trapping the intracel-
lular NO with EPR detection as described by Cai et al.
[29] with minor changes. Briefly, lungs perfused with
ice-cold PBS were excised and cut into small pieces and
placed into 0.1 ml Krebs Hepes buffer (NaCl 99 mM, KCl
4.7 mM, CaCl2 2.5 mM, MgSO4 1.2 mM, NaHCO3
25 mM, KH2PO4 1.03 mM, glucose 5.6 mM, HEPES
20 mM) on a 24-well plate. The buffer was bubbled for at
least 30 min with argon gas on ice to remove oxygen
prior to use. Then 2.25 mg of FeSO4 × 7H2O/10 ml
and 3.6 mg of DETC/10 ml were dissolved separately
in argon-bubbled buffer, to obtain final concentrations 0.8
mM and 1.6 mM, respectively, mixed, and immediatelyadded to the tissue samples (0.25 ml per well). The tissues
were placed in an incubator at 37 °C and incubated for
90 min in an air atmosphere. Tissue samples were then
collected, weighed, introduced into 1-ml insulin syringes,
and snap-frozen in liquid nitrogen. Measurements of
Fe2(DETC)2-NO signals in frozen samples were per-
formed in a finger Dewar using an EMX Plus Bruker spec-
trometer with the following settings: microwave power,
10 mW; modulation amplitude, 0.8 mT; scan width, 11.5
mT; scan time, 61.44 s; number of scans, 4. The results
were collected, and the amplitude of the characteristic
NO triplet spectrum was analyzed using Eleana software.
Quantitative assessment of Snail expression in the
pulmonary circulation
Formalin-fixed and paraffin-embedded lungs were cut
into 5-μm slices. Antigen retrieval was performed ac-
cording to the standard protocol. To visualize expression
of Snail, the slices were incubated with primary
anti-Snail antibody (ab53519; Abcam) and secondary bi-
otinylated donkey anti-goat antibodies (705-065-147;
Jackson ImmunoResearch) concomitantly with ABC
vector complex. For each slice, 10 randomly chosen
nonobstructed arteries were photographed with a BX51
microscope (objective 20×) equipped with the virtual mi-
croscopy system dotSlide (Olympus, Japan) and the
length of Snail-positive fragment(s) within the artery was
manually measured and expressed as the percentage of
the entire circuit of the particular artery. At the same
time, the representative images of the investigated arter-
ies were assessed for their patency (i.e., obstruction with
blood clot or cancer cells) by a blinded investigator.
Measurement of pulmonary endothelium permeability by
Evans blue
Subsequent to anesthesia (100 mg/kg ketamine + 10 mg/
kg xylazine, i.p.), mice were injected via the femoral vein
with a solution of Evans blue (EB, 60 kDa) dye (Sigma
Aldrich) at a dose of 4 ml/kg. Injected dye solution,
composed of 2% EB in 0.9% saline, was left to circulate
for 10 min, and then the mouse chest was surgically
opened and concurrently perfused via left (systemic cir-
culation) and right (pulmonary circulation) ventricles
with PBS for 15 min. Lungs were isolated, dry weighed,
and homogenized in 200 μl of 50% TCA (dissolved in
distillated water). The homogenate was frozen and kept
at − 20 °C for EB concentration measurement. Subse-
quent to thawing, homogenates were centrifuged (at
10625 × g for 12 min at 4 °C), and the supernatant was
collected and diluted with 1:3 volumes of 95% ethanol
prior to photospectrometric (Synergy 4; Bio-Tek) deter-
mination of EB concentration (fluorescence: excitation
at 590 nm, emission at 645 nm, absorbance at 620 nm).
Results were normalized to the tissue weight.
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Lungs were perfused with PBS, excised, rinsed in saline,
dried with tissue paper, weighed, cut into small pieces, and
snap-frozen in liquid nitrogen; the samples were stored at
− 80 °C. For western blot analysis, whole lungs were ho-
mogenized and whole lung lysates were used. Lungs were
homogenized in the lysis buffer (Thermo Fisher Scientific)
for protein extraction with protease and phosphatase inhib-
itors. Protein concentration was measured with the use of a
BCA assay. Subsequently, the samples from at least six
mice in each experimental group were pooled together in
such a way that an equal amount of protein from each sam-
ple was dissolved in an equal volume of the lysis buffer for
each mouse in the group to ensure the equal representation
of each individual sample in the pooled specimen. After
addition of loading buffer, samples were heated at 95 °C for
5 min and then frozen at − 80 °C. Each time, an equal
amount of protein from pooled samples was loaded and
run on the gel, and then transferred to a nitrocellulose
membrane, blocked with 5% dry milk, and incubated with
the primary antibodies directed against the following anti-
gens: p(S1177)eNOS (ab195944; Abcam), eNOS (610,296;
BD Transduction Laboratories), VEGFA (ab68334; Abcam),
VEGFR2 (ab39256; Abcam), Ang-1 (ab8451; Abcam),
Ang-2 (PA5-27297; Thermo Fisher Scientific), VCAM-1
(CBL1300; Merck), Slit2 (ab134166; Abcam), ROBO4
(orb101060; Biorbyt), ROBO1 (ab85312; Abcam), TGF-β1
(ab155264; Abcam), VE-CAD (sc-6458; Santa Cruz Bio-
technology), CD31 (NBP1-71663H; Novus Biologicals),
vWF (ab9378; Abcam), MMP-2 (ab19167; Abcam),
MMP-9 (ab19016; Abcam), and MMP-14 (sab4501901;
Sigma Aldrich). The appropriate horseradish peroxidase
(HRP)-conjugated secondary antibodies were from Santa
Cruz Biotechnology (sc-2020, sc-2004, and sc-2005). Equal
protein loading was confirmed after transfer onto mem-
branes, as measured by a stain-free technique provided by
Bio-Rad [30]. Densitometric assessment of band intensity
was performed using ImageJ. The results are presented as
the fold change of control corresponding to healthy mice.
Total protein was used as a loading control.
Measurement of platelet basal activity and ADP-induced
reactivity
Blood samples were collected into a syringe containing
3.8% citrate (blood/citrate at 10:1 (v/v)) from the right
heart ventricle. A blood count was performed using the
animal blood counter Vet abc (Horiba Medical, France).
The samples designated for flow cytometric measure-
ments were diluted with saline and washed with Tyrode
buffer. Each sample was double stained with four anti-
bodies that included platelet-specific antigen GpIIbIIIa
(CD41/61), either FITC or PE conjugated, for platelet
identification and one of four platelet activation
markers—PE-conjugated active form of GPIIb/IIIa andP-selectin antibodies, FITC-conjugated fibrinogen, or von
Willebrand (vWF) factor—representing platelet binding
capacity. Platelets were identified based on their
forward-scatter and side-scatter characteristics and were
gated on the basis of the expression of platelet-specific
antigen CD41/61 (see Additional file 1). Isotype control
antibodies, either FITC or PE conjugated, were used to as-
sess nonspecific binding for each individual sample. Basal
and ADP-induced (20 μM) activation of circulating plate-
lets was assessed on the basis of the measured expression/
binding level of surface membrane antigens expressed as a
percentage of all platelets above the isotype control fluor-
escent signal and the median fluorescence intensity (MFI).
Flow cytometric analyses of platelet activation were per-
formed using flow cytometry software (LSRII and FACS/
Diva version 6.0, respectively; Becton Dickinson, Oxford,
UK). Measurements were made on a logarithmic scale and
at least 10,000 events were collected for each sample. Ap-
propriate color compensation was determined in samples
singly stained with either FITC-conjugated anti-CD41/61
or PE-conjugated anti-CD41/61.
Statistical analysis
Data were presented as mean ± SD (box) with outliers or
median of the data and interquartile range (IQR) (box,
from lower (25%) to upper (75%) quartile) with outliers
depending on normality of the data distribution that was
tested with the Shapiro–Wilk normality test, homogeneity
of variances that was tested with Barlett’s test, and the
variable scale. Statistical significance was assessed with a
one-way ANOVA or Kruskall–Wallis test followed by a
post-hoc Tukey’s or Dunn’s multiple comparison test,
respectively. Some variables nonconforming with the nor-
mal distribution and/or variance homogeneity were Box–
Cox transformed and analyzed with parametric tests,
otherwise they were analyzed with nonparametric infer-
ence tests. Only P < 0.05 was considered significant.
Results
Development of pulmonary metastasis and systemic
inflammation in the orthotopic murine 4T1 breast cancer
model
The first pulmonary metastatic nodules were detected
in the 3rd week after breast cancer cell injection
(Fig. 1d, g), while the primary tumor became detectable
in the 2nd week after cancer cell inoculation (Fig. 1i).
Then, both the number of pulmonary metastases and
the primary tumor weight and volume increased pro-
gressively (Fig. 1). The weight of the lungs was signifi-
cantly increased only in the 5th week compared to
control healthy mice (Table 1), since only at that time
was the presence of large metastastic foci in the lungs
detected (Fig. 1f, g). The appearance of the first meta-
static nodules in the lungs in the 3rd week after breast
Fig. 1 Tumor growth and development of pulmonary metastasis in 4T1 breast cancer progression in mice. a Lung cross-section of
healthy control mouse. b–f Mice injected orthotopically with 4T1 breast cancer cells (see Methods). Designated groups of animals
sacrificed every 7 days to assess number of pulmonary metastases in 1st (b), 2nd (c), 3rd (d), 4th (e), and 5th (f) week after 4T1 breast
cancer inoculation (black arrowheads point to metastatic nodules in lungs) on lung cross-sections stained with H&E. Scale bar represents
200 μm. g Number of pulmonary metastases in mice from 1st to 5th week after 4T1 cancer cell inoculation; n = 10 for 1st –4th week
and n = 14 for 5th week. h Weight of primary tumor in consecutive weeks after 4T1 cancer cell inoculation; n = 30 for 1st –4th week and
n = 68 for 5th week. (i) Primary tumor volume; n = 30 for 1st –4th week and n = 68 for 5th week. (g–i) Data presented as median and
IQR. Black circle indicates outlier. Depending on variable scale, normality of distribution, and variance homogeneity, data analyzed with
Kruskal–Wallis test followed by Dunn’s multiple comparison test. Statistical significance vs mice in 1st week after 4T1 cancer cell
inoculation at *P < 0.05 and ***P < 0.001
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temic leukocytosis and increased spleen weight
(Table 1), indicating the onset of systemic inflamma-
tion. Pulmonary metastasis was also associated withprogressive degradation of elastin fibers (Fig. 2a–g)
and an increase in the expression of metalloproteinase
2, 9, and 14 (MMP-2, MMP-9, MMP-14) in the lungs
3 and 4 weeks after breast cancer cell injection,
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Fig. 2 Changes in pulmonary elastin and metalloproteinase expression in 4T1 breast cancer progression in mice. Paraffin-embedded lungs cut
into slices to visualize elastin (see Methods). a–f above Representative image of (a) healthy control and 1st (b), 2nd (c), 3rd (d), 4th (e), and 5th (f)
week after 4T1 cancer cell inoculation. Scale bar represents 50 μm. a–f below Corresponding segmentation. g Differences in relative elastin
expression (dark gray pixels corresponding to elastin vs light gray pictures corresponding to lung tissue), shown as mean ± SD. Black circle
indicates outlier; n = 20 for healthy control mice and mice in 1st, 2nd, and 4th week of disease; n = 21 for mice in 3rd week of disease; n = 19 for
mice in 5th week of disease. Data subjected to Box–Cox transformation and analyzed by one-way AVOVA followed by Tukey’s multiple
comparison test due to normality of distribution and homogeneity of variances. Statistical difference vs healthy control mice at *P < 0.05 and ***P
< 0.001. h MMP-2, MMP-9, and MMP-14 expression in pooled samples (n = 6) (see Methods). MMP-2, higher band indicates inactive isoform while
lower band indicates active isoform. MMP-14, higher band corresponds to active monomer while lower band corresponds to domains after
catalytical cleavage. Results presented as fold change vs control sample corresponding to healthy mice. Total protein after transfer was used as
loading control
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modeling accompanying the advanced stage of metas-
tasis progression.
Progressive impairment of NO production in lungs in the
orthotopic murine 4T1 breast cancer model
Local NO production in the lungs was impaired already
in the 1st week after 4T1 cell injection (Fig. 3a) and
remained significantly compromised thereafter in 4T1
breast cancer-bearing mice. The progressive fall in NO
production in mice injected with 4T1 cells corresponded
with progressive decrease in eNOS phosphorylation of
S1177 observed throughout the progression of the dis-
ease after 4T1 cancer cell inoculation (Fig. 3b).
Expression of endothelial–mesenchymal transition
markers in pulmonary endothelium in the orthotopic
murine 4T1 breast cancer model
Expression of Snail in the lungs of mice orthotopically
injected with 4T1 breast cancer cells, compared with
healthy control mice, was higher in the endothelial layer
of small arteries as soon as 1 week after cancer cell in-
jection and stayed elevated throughout the entire pro-
gression of the disease, except for the terminal time
point 5 weeks after 4T1 breast cancer cell inoculation
(Fig. 4a–g). TGF-β1 expression in the lungs was slightlyFig. 3 Pulmonary NO production and eNOS phosphorylation in orthotopic 4
mean ± SD. Data were Box–Cox transformed and analyzed with one-way AN
1st–4th week of disease; n = 19 for 5th week of disease. Black circle indicates
production measured (see Methods). Statistical significance vs healthy contro
eNOS and p(S1177)eNOS levels during progression of breast cancer used to c
expressed as fraction of total eNOS level in lungs of control healthy mice for w
fold change vs control sample corresponding to healthy mice. Total protein a
p(S1177)eNOS and eNOS levels in pooled samples in all experimental groups
experimental group (see Methods). AU arbitrary units, eNOS endothelial nitricincreased only in the 1st week after 4T1 breast cancer cell
inoculation (Fig. 4h). The phenotypic change of pulmonary
endothelium compatible with endothelial–mesenchymal
transition, evidenced by downregulation of endothelium-
specific proteins such as VE-CAD, CD31, vWF, or VEGFR2,
seemed to be evident 3 weeks after cancer cell inoculation
(Fig. 4i), concomitant with the early phase of metastasis
(Fig. 1g).
Changes in pulmonary endothelial barrier function in the
orthotopic murine 4T1 breast cancer model
Increased permeability of pulmonary endothelium
expressed as increased deposition of Evans blue (EB) in
the lungs of 4T1 breast cancer-bearing mice was found
only in the 3rd week after cancer cell inoculation
(Fig. 5a), indicating an evident increase in endothelial
permeability at the early phase of metastasis. Then, EB
leakage from the circulation into the lungs started to de-
crease and, finally, it was lower than in healthy control
mice in the 5th week after cancer cell inoculation. De-
creasing EB penetration into the lungs of mice in the 4th
and 5th weeks of the disease appeared to be due to the
occlusion of pulmonary vessels by cancer cells proliferat-
ing in their lumen (Fig. 5b–d), rather than due to
changes in pulmonary endothelial permeability itself. In-
creased permeability of the pulmonary endothelium inT1 breast cancer model in mice. a NO production in lungs, presented as
OVA followed by Tukey’s multiple comparison test; n = 10 for control and
outlier. Perfused lungs were excised from euthanized animals and NO
l mice at **P < 0.01 and ***P < 0.001. b Densitometric data presenting
alculate relative eNOS phosphorylation at serine 1177 (black circle)
hich an arbitrary value of 1 was ascribed. Western blot image presents
fter transfer was used as loading control. Western blot image shows
obtained by pooling lung homogenates from six mice in each
oxide synthase, NO nitric oxide
Fig. 4 Snail and EndMT-related protein expression in lungs in orthotopic murine 4T1 breast cancer model. a–g Expression of Snail (see Methods).
Representative micrographs of arteries from control (a), 1st (b), 2nd (c), 3rd (d), 4th (e), and 5th (f) week after 4T1 cell inoculation. Scale bar represents
50 μm. g Quantitative expression of Snail in endothelial layer of small arteries of each group, shown as median and IQR. Black circle indicates outlier.
Data analyzed with Kruskal–Wallis test followed by Dunn’s multiple comparison test; n = 61, n = 60, n = 58, n = 60, n = 60, and n = 59 for control, 1st,
2nd, 3rd, 4th and 5th week. Statistical significance vs healthy control group at ***P < 0.001. h, i TGF-β1 (I, TGF-β1 and TGF-β2 heterodimers; II, TGF-β1
homodimers; III, full-length inactive TGF-β1; IV, mature TGF-β1) (h) and VE-CAD (vascular endothelium cadherin), CD31 (cluster of differentiation 31),
vWF (von Willebrand factor), and VEGFR2 (vascular endothelial growth factor receptor 2) (i) levels determined by western blot analysis in pooled (n = 6)
samples in control and 4T1 breast cancer-bearing mice from the 1st to 5th week after 4T1 cancer cell inoculation (see Methods). Results presented as
fold change vs control sample corresponding to healthy mice. Total protein after transfer was used as loading control
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with a transient increase in VEGFA and VCAM-1 ex-
pression in the lungs (Fig. 5e).
Progressive downregulation of Slit2–ROBO4–ROBO1
pathway in the orthotopic murine 4T1 breast cancer
model
Slit2 maintains endothelium integrity via interaction of its
full-length or N-terminal part with endothelium-specific
ROBO4 via ROBO1 [19, 31, 32]. Full-length Slit2 was un-
detectable in lungs homogenates of both control and 4T1
breast cancer-bearing mice, while its N-terminal fragment
was found both in healthy control and breast-cancer bear-
ing mice (Fig. 6). Upregulation of both receptors ROBO4
and ROBO1 was detected only in the 1st week after 4T1
cell injection when the level of N-terminal Slit2 binding
ROBO receptors was still preserved. Starting from the
2nd week after cancer cell inoculation, the Slit2–ROBO4–ROBO1 protective signaling pathway was gradually down-
regulated in the lungs of 4T1 breast cancer-bearing mice.
Changes in basal platelet activation and ADP-induced
reactivity in the orthotopic murine 4T1 breast cancer
model
Basal platelet activation and ADP-induced reactivity
were both assessed as the percentage of platelets ex-
pressing P-selectin, active form of GPIIb/IIIa, vWF, and
fibrinogen bound to platelet surface in their entire popu-
lation (Fig. 7) as well as median expression of these anti-
gens on the platelet surface (Fig. 8). The signs for
activation of platelets in the early phase of metastasis
and loss of reactivity to stimuli afterward were detected.
The percentage of platelets expressing P-selectin and ac-
tive form of GPIIb/IIIa peptide in basal condition or
upon ADP stimulation were not different between
healthy control and 4T1 breast cancer-bearing mice
Fig. 5 Pulmonary endothelium permeability in orthotopic murine 4T1 breast cancer model. a Evans blue (EB) deposition in lungs (see Methods),
presented as mean ± SD. Black circle indicates outlier. Data analyzed with one-way ANOVA followed by Tukey’s multiple comparison test based
on normality of distribution and homogeneity of variances; n = 20 for control and 1st and 3rd week; n = 18 for 2nd and 4th week; n = 10 for 5th
week. Statistical significance vs healthy control group at *P < 0.05 and P** < 0.01. b–d Lung slices stained to visualize transcription factor Snail
(see Methods), which is highly expressed in secondary nodules composed of metastatic 4T1 breast cancer cells. Black arrows point to pulmonary
blood vessels of mice in 3rd (b), 4th (c), and 5th (d) week after 4T1 cancer cell inoculation to visualize that in 4th and 5th weeks some pulmonary
vessels were occluded by metastatic cancer cells proliferating in their lumen. Scale bar represents 50 μm. e VEGFA and VCAM-1 expression
determined by western blot analysis in pooled samples (n = 6) corresponding to healthy control and 4T1 breast cancer-bearing mice in 1st–5th
week after 4T1 cancer cell inoculation (see Methods). Results presented as fold change vs control sample. Total protein after transfer was used as
loading control. AU arbitrary units, VCAM vascular cell adhesion molecule, VEGFA vascular endothelial growth factor A
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tions was increased in 4T1 breast cancer-bearing mice
as compared with control mice 1–3 weeks after 4T1
cancer cell inoculation, reaching significance 2 weeks
after cancer cell inoculation. Similarly, vWF binding to
platelets was also increased 1–3 weeks after cancer cell
inoculation (not significantly). In contrast, 5 weeks after
4T1 breast cancer cell inoculation, the capacity of plate-
lets to bind fibrinogen and vWF was significantly dimin-
ished in basal conditions as well as after ADP
stimulation (Fig. 7c, d). As shown in Fig. 8, median ex-
pression of P-selectin, active form GPIIb/IIIa, vWF, and
bound fibrinogen on the unstimulated platelet surface
was not altered in 4T1 breast cancer-bearing mice as
compared with controls. However, after ADP stimula-
tion, platelet surface expression of vWF and fibrinogen
but not P-selectin and active form of GPIIb/IIIa was in-
creased to a lesser extent in 4T1 breast cancer-bearing
mice as compared with healthy controls (Fig. 8c, d).Discussion
This study comprehensively characterized step-by-step
progression of pulmonary endothelial dysfunction during
4T1 breast cancer growth and metastasis to establish at
which stage endothelial impairment and mesenchymal
transformation of endothelial cells (EndMT) occurs in
metastatic organs in relation to the formation of metas-
tasis. We found that NO production in pulmonary endo-
thelium was impaired already at the premetastatic phase
of the disease concomitantly with decreased eNOS phos-
phorylation in the lungs (Fig. 3). However, even though
the expression of Snail transcription factors in the pul-
monary endothelium (Fig. 4a–g) and TGF-β1 in the
lungs (Fig. 4h) (both known to be main drivers of
EndMT) were increased in relation to healthy controls
already in the premetastatic stage (1st week), the onset
of functional phenotypic switch of pulmonary endothe-
lium known as EndMT seemed to take place no earlier
than the 3rd week after breast cancer cell inoculation
Fig. 6 Slit2–ROBO4–ROBO1-dependent signaling in orthotopic murine 4T1 breast cancer model. Slit2 (axon guidance molecule), ROBO4 and
ROBO1 (roundabout 1 and 2) expression determined by western blot analysis in pooled samples (n = 6) corresponding to healthy control and 4T1
breast cancer-bearing mice from 1st to 5th week after 4T1 cancer cell inoculation (see Methods). Full-length Slit2 ~ 200 kDa (U) is proteolytically
cleaved, giving rise to an N-terminal fragment ~ 140 kDa (N) and a C-terminal fragment ~ 55 kDa (C). Only full-length and N-terminal peptides
can bind ROBO proteins. Therefore, representative picture of entire membrane probed with primary anti-Slit2 antibody presented; we are unsure
about identity of the ~ 75 kDa band detected with anti-Slit2 antibody. Results presented as fold change vs control sample corresponding to
healthy mice. Total protein after transfer was used as loading control. ROBO roundabout family of receptors, Slit axon guidance molecule
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activated, as evidenced by higher VCAM-1 expression
(Fig. 5e), and endothelial barrier integrity was lost, as visu-
alized by increased deposition of EB in the lungs (Fig. 5a).
Development of EndMTalso seemed to coincide with pro-
gressive decrease in pulmonary elastin levels (Fig. 2a–g)
and increased expression of proteolytic enzymes like me-
talloproteinase 2, 9, and 14 (MMP-2, MMP-9, MMP-14)
in the lungs (Fig. 2h), indicating metastatic tissue remodel-
ing at this stage. To summarize, our results identified de-
creased eNOS activity and phosphorylation resulting in an
NO-deficiency state as an early event in breast cancer pul-
monary metastasis, that occurs prior to the decrease in ex-
pression of endothelium-specific markers that indicates
functional phenotypic switch of pulmonary endothelium
toward a mesenchymal phenotype (EndMT), coinciding
with development of the first metastatic nodules in the
lungs and metastatic tissue remodeling.
Recently, it has been postulated that endothelial cells
can actively augment metastatic extravasation through
the shift in their phenotype known as endothelial–mes-
enchymal transition [26]. Moreover, in the case of the
lungs, transformed endothelial cells can represent asignificant source of fibroblasts [33] that can enrich the
population of cancer-associated fibroblasts (CAFs) that
constitute key components of tumor stroma [26]. There-
fore, hampering or preventing EndMT could directly
affect settlement of cancer cells in the lungs. In the
present work, however, we demonstrated that the pheno-
typic switch of pulmonary endothelium toward mesenchy-
mal cells (EndMT, evidenced by downregulation of
VE-CAD, CD31, vWF, or VEGFR2 [34]) is a relatively late
response in murine 4T1 metastatic breast cancer. It coin-
cides with increased endothelial permeability and early
metastasis but is preceded by a clear-cut NO-deficiency
state, that was detected as early as 1 week after 4T1 cancer
cell inoculation in the premetastatic stage, even before the
primary tumor was detectable. These findings suggest that
early endothelial dysfunction in the lungs, indicated by
NO deficiency rather than EndMT, might represent a pri-
mary regulatory target to prevent early pulmonary metas-
tasis. Indeed, NO was shown to inhibit heteroadhesion of
cancer cells to endothelial cells [5]. Moreover, decreased
NO levels in the circulation have been shown to promote
EndMT [35], while eNOS stimulation had the opposite ef-
fect [36]. However, the role of NO bioavailability in
Fig. 7 Platelet basal activity and ADP-induced reactivity in orthotopic murine 4T1 breast cancer model. Platelet basal activation and their ADP-
induced reactivity assessed as percentage of platelet surface expression of P-selectin (a), active form of receptor GPIIb/IIIa (b), von Willebrand
factor (vWF) binding (c), and fibrinogen binding (d) (see Methods), presented as median and IQR. Black circle indicates outlier. Data analyzed with
Kruskal–Wallis test followed by Dunn’s multiple comparison test since they either did not display normal distribution and/or their variances were
heterogeneous. a n = 10, n = 7, n = 9, n = 7, n = 8, and n = 12 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week, respectively; and n = 9, n = 7, n
= 8, n = 6, n = 6, and n = 12 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week after ADP stimulation. b n = 10, n = 7, n = 9, n = 7, n = 8, and n =
13 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week, respectively; and n = 10, n = 7, n = 9, n = 7, n = 7, and n = 13 for healthy control, 1st, 2nd,
3rd, 4th, and 5th week after ADP stimulation. c n = 10, n = 7, n = 8, n = 7, n = 8, and n = 18 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week,
respectively; and n = 10, n = 7, n = 9, n = 7, n = 7, and n = 19 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week after ADP stimulation. d n = 10, n
= 7, n = 8, n = 7, n = 8, and n = 20 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week, respectively; and n = 9, n = 7, n = 9, n = 7, n = 8, and n = 20
for healthy control, 1st, 2nd, 3rd, 4th, and 5th week after ADP stimulation. Statistical significance at level of *P < 0.05, **P < 0.01, and ***P < 0.001
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and its antimetastatic effects seem to depend on multiple
factors (i.e., disease stage [37]). Indeed, while Buczek et al.
[38] showed that both local as well as systemic NO defi-
ciency was present in the premetastatic stage of 4T1
breast cancer, increased systemic NO bioavailability at the
advanced stage was associated with increased mortality of
4T1 breast cancer-bearing mice [39].
Interestingly, in spite of early NO deficiency (Fig. 3),
the onset of functional EndMT in the lungs of 4T1
breast cancer-bearing mice seemed to be delayed until
the 3rd week, in spite of the increased expression of
Snail transcription factors in the pulmonary endothelium
(Fig. 4a–g) and TGF-β1 in the lungs (Fig. 4h) known to
drive mesenchymal shift of endothelial cells [22]. We are
tempted to speculate that the delayed onset of EndMT
could result from the activation of Slit2 and its recep-
tors’ ROBO1–ROBO4-dependent signaling in the 1st
week of breast cancer progression (Fig. 6), since Slit2
was previously reported to inhibit both TGF-β [40] andSnail [41] signaling, both involved in the triggering of
mesenchymal transformation of endothelial cells [20,
22–25, 34]. When expression of Slit2 receptors started to
decline progressively (2nd week of disease) (Fig. 6), a simi-
lar trend was observed in the case of VE-CAD, CD31,
vWF, or VEGFR2 (Fig. 4i), indicating the onset of func-
tional EndMT [34]. However, although this new role of
Slit2-dependent signaling in inhibition of EndMT in ma-
lignant disease is emerging, mechanistic confirmation is
still missing. One possibility involves Slit2-dependent in-
hibition of Notch signaling [42] that is known to trigger
EndMT [43]. Last but not least, delayed onset of EndMT
in the lungs of 4T1 breast cancer-bearing mice could also
have been associated with other Slit2-independent signal-
ing pathways, such as bFGF-dependent signaling counter-
acting TGF-β signaling [44].
The initiation of functional EndMT in the lungs of
breast cancer-bearing mice that seemed to take place at
the beginning of the metastatic phase did not coincide
with the rise in TGF-β1 levels in the lungs at that time
Fig. 8 Basal and ADP-stimulated MFI of platelet antigenes in orthotopic murine 4T1 breast cancer model. Median expression of P-selectin (a),
active form of GPIIb/IIIa (b), bound von Willebrand factor (vWF) (c), and fibrinogen (d) shown as median fluorescence intensity (MFI). Data
presented as median and IQR. Black circle indicates outlier. Data analyzed with Kruskal–Wallis test followed by Dunn’s multiple comparison test
since they either did not display normal distribution and/or their variances were heterogeneous. a n = 10, n = 7, n = 9, n = 7, n = 8, and n = 12 for
healthy control, 1st, 2nd, 3rd, 4th, and 5th week, respectively; and n = 9, n = 7, n = 8, n = 6, n = 6, and n = 12 for healthy control, 1st, 2nd, 3rd, 4th,
and 5th week after ADP stimulation. b n = 10, n = 7, n = 9, n = 7, n = 8, and n = 13 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week, respectively;
and n = 10, n = 7, n = 9, n = 7, n = 7, and n = 13 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week after ADP stimulation. c n = 10, n = 7, n = 8, n = 7,
n = 8, and n = 18 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week, respectively; and n = 10, n = 7, n = 9, n = 7, n = 7, and n = 19 for healthy control,
1st, 2nd, 3rd, 4th, and 5th week after ADP stimulation. d n = 10, n = 7, n = 8, n = 7, n = 8, and n = 20 for healthy control, 1st, 2nd, 3rd, 4th, and 5th
week, respectively; and n = 9, n = 7, n = 9, n = 7, n = 8, and n = 20 for healthy control, 1st, 2nd, 3rd, 4th, and 5th week after ADP stimulation. Statistical
significance at level of **P < 0.01 and ***P < 0.001. AU arbitrary units
Smeda et al. Breast Cancer Research  (2018) 20:86 Page 13 of 15(Fig. 4h) and, therefore, must have been associated with
activation of TGF-β-independent mechanisms. Recently,
Krenning et al. [22] reported that EndMT could also be
triggered by disturbances in shear stress and activation of
mechanoreceptors such as VE-CAD, CD31, or VEGFR2
on endothelial cells. The level of VEGFA in the lungs of
4T1 breast cancer-bearing mice was transiently increased
in the 3rd week of the disease (Fig. 5e) and such a local
rise in VEGFA has been recently associated with oscilla-
tory turbulent flow (Lena Claesson-Welsh, personal com-
munication, the 2nd Nov, 2016) that could activate the
mechanoreceptors on endothelial cells. Last but not least,
yet another possible trigger for EndMT in pulmonary me-
tastasis and pulmonary remodeling is hypoxia. Therefore,
further investigation of signaling pathways involved in
triggering EndMT of pulmonary endothelium in breast
cancer progression is needed, but is beyond the scope of
this work.
Effective extravasation of cancer cells could also be actively
promoted by platelets. Once activated, platelets express ontheir surface or release various tumor-promoting factors,
protect circulating tumor cells (CTCs) from immune attack,
or promote extravastation of CTCs/tumor angiogenesis [10].
In the present work, we found the signs for activation of
platelets in the early phase of metastasis (Fig. 7c, d) and very
early loss of their reactivity in response to ADP ex vivo
(Fig. 8c, d), confirming a possible involvement of platelets in
the early host response to circulating cancer cells [10, 45].
However, although activation of platelets initiates vascular
inflammation associated with various diseases [15], their
contribution to early pulmonary endothelial dysfunction
and/or EndMT in breast cancer progression still needs to be
verified.
Conclusions
This study comprehensively described progression of
endothelial dysfunction in the lungs, being the primary
site of metastasis in Balb/C mice bearing breast cancer.
The major finding was that pulmonary endothelium dys-
function, in terms of compromised NO production and
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breast cancer progression. It preceded the decrease in
expression of endothelium-specific proteins indicating
onset of the phenotypic switch of pulmonary endothelium
toward the mesenchymal phenotype (EndMT) and devel-
opment of first metastatic nodules in the lungs. These
findings suggest that early endothelial dysfunction fea-
tured by NO deficiency in the lungs rather than EndMT
might represent a primary regulatory target to prevent
early pulmonary metastasis. However, further studies are
needed to establish whether preventing the NO deficiency
in the function of pulmonary endothelium at the premeta-
static stage (i.e., by locally increasing NO bioavailability)
could indeed delay or inhibit pulmonary metastasis. It also
remains a matter of debate whether targeting pulmonary
endothelial mesenchymal transition at the metastatic stage
of a malignant disease (e.g. by inhibiting mesenchymal
transformation of endothelial cells as by preventing
IL-1β-dependent signaling [46, 47]) could improve disease
outcomes.
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Additional file 1: Platelet population gating in LSRII using FACS/Diva
version 6.0 software. Gating strategy for one of four antibodies where
platelets positive for GpIIbIIIa (CD41/61) express active form of GpIIbIIIa after
stimulation with ADP (20 μM). Population of platelets selected from diluted
whole blood sample in two steps: firstly, based on forward-scatter (FFC) and
side-scatter (SSC) characteristics; secondly, based on CD41/61 antigen
positive expression. Finally, expression level of activation marker (GpIIbIIIa
active form) measured in selected population of platelets. (TIF 132 kb)
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